Menu
Fechar
hrs4r
 I want to donate

XAVIER HERNÁNDEZ YAGÜE

Precision Oncology in Girona
Firma
XAVIER HERNÁNDEZ-YAGÜE
Position
Investigador/a Pre-doctoral – R1
Predoctoral Researchers – R1
Projectes
Publicacions

Projectes

Precision Oncology in Girona

Avaluació del grau de resposta patològica tumoral al tractament amb inhibidors de l’angiogènesi i del factor de creixement epidèrmic, en combinació a quimioteràpia, de les metàstasi hepàtiques de càncer colorectal ressecades

Codi oficial: VEGF/EGFR Start date:11/06/2022 Data fi: 17/10/2024 Investigador/a principal: XAVIER HERNÁNDEZ YAGÜE Organisme finançador: FUNDACIÓ ACADÈMIA CIÈNCIES MÈDIQUES

Publicacions

Cabrero-de Las Heras S, Hernández-Yagüe X, González A, Losa F, Soler G, Bugés C, Baraibar I, Esteve A, Pardo-Cea MÁ, Ree AH, Martínez-Bosch N, Nieva M, Musulén E, Meltzer S, Lobato T, Vendrell-Ayats C, Queralt C, Navarro P, Montagut C, Grau-Leal F, Camacho D, Legido R, Mulet-Margalef N, Martínez-Balibrea E

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment.

BIOMEDICINE & PHARMACOTHERAPY, 2024, 176, 116857-116857 dx.doi.org/10.1016/j.biopha.2024.116857
Trilla-Fuertes L, Gámez-Pozo A, Nogué M, Busquier I, Arias F, López-Campos F, Fernández-Montes A, Ruiz A, Velázquez C, Martín-Bravo C, Pérez-Ruiz E, Asensio E, Hernández-Yagüe X, Rodrigues A, Ghanem I, López-Vacas R, Hafez A, Arias P, Dapía I, Solís M, Dittmann A, Ramos R, Llorens C, Maurel J, Campos-Barros Á, Fresno Vara JÁ, Feliu J

Utility of <i>CYP2D6</i> copy number variants as prognostic biomarker in localized anal squamous cell carcinoma

CANCER, 2023, 129, 2581-2592 dx.doi.org/10.1002/cncr.34797
Aparicio, J, Manrique, ACV, Capdevila, J, Boza, FM, Galvan, P, Richart, P, Oliveres, H, Paez, D, Hernando, J, Serrano, S, Vera, R, Hernandez-Yague, X, Gallego, RA, Riesco-Martinez, MC, de Albeniz, XG, Maurel, J

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24, 2155-2165 dx.doi.org/10.1007/s12094-022-02868-x
Planellas P, Cornejo L, Rodríguez-Hermosa JI, Maldonado E, Timoteo A, Hernández-Yagüe X, Farrés R, Codina-Cazador A

Is Metformin Associated With Improved Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer?

JOURNAL OF SURGICAL RESEARCH, 2021, 268, 465-473 dx.doi.org/10.1016/j.jss.2021.06.079
Planellas Giné P, Cornejo Fernández L, Salvador Rosés H, Buxó Pujolras M, Farrés Coll R, Hernandez Yague X, Canals Subirats E, Gil Garcia J, Rodríguez Hermosa JI, Codina Cazador A

Delaying surgery by more than 10 weeks after long-course neoadjuvant radiotherapy in locally advanced rectal cancer patients improves pathologic complete response

Updates in Surgery, 2020, 72, 453-461 dx.doi.org/10.1007/s13304-020-00747-0
Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, Lopez-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA

Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.

INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 39, 1455-1479 dx.doi.org/10.3892/ijo.2011.1155
Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Queralt B, Báez L, Guardeño R, Hernández-Yagüe X, Martin-Castillo B, Brunet J, Menendez JA

Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.

JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112, 10-29 dx.doi.org/10.1002/jcb.22952

Formulari de contacte

About IDIBGI!

 menu